Sino Biopharmaceutical Limited (FRA:SMZ1)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.88B +35.2% |
| Revenue (ttm) | 3.88B +10.3% |
| Net Income | 285.35M -33.0% |
| EPS | 0.02 -32.1% |
| Shares Out | n/a |
| PE Ratio | 38.13 |
| Forward PE | 18.96 |
| Dividend | 0.01 (1.60%) |
| Ex-Dividend Date | Aug 29, 2025 |
| Volume | n/a |
| Average Volume | 678 |
| Open | 0.6024 |
| Previous Close | 0.6190 |
| Day's Range | 0.6024 - 0.6024 |
| 52-Week Range | 0.4241 - 0.9926 |
| Beta | n/a |
| RSI | 39.15 |
| Earnings Date | Mar 26, 2026 |
About Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]
Financial Performance
In 2025, Sino Biopharmaceutical's revenue was 31.83 billion, an increase of 10.28% compared to the previous year's 28.87 billion. Earnings were 2.34 billion, a decrease of -33.04%.
Financial numbers in CNY Financial StatementsNews
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the compan...
China's health-care sector may be next to face regulatory crackdown, says economist
Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
Cancer killed far more people around the world than Covid-19 in 2020